East Oregonian

Hannah Storm, Award-Winning Broadcaster and DCIS Patient Advocate, Partners with PreludeDx to Share How the DCISionRT Test Gave Her Confidence in Her Treatment Decision

Soon after her diagnosis, Storm’s physician team ordered PreludeDx’s DCISionRT®, the only risk assessment test that predicts radiation therapy (RT) benefit in DCIS patients, to be run on her tumor ...
KTLA

The DCISionRT® Test Result is the Most Important Factor Determining Clinician Treatment Recommendations - Findings from Multicenter PREDICT Study of 2,007 Patients

LAGUNA HILLS, Calif., June 26, 2024 /PRNewswire/ -- Prelude Corporation (PreludeDx ®), a leader in precision diagnostics for early-stage breast cancer, announced an important advancement in the field ...
FOX8 Cleveland

PreludeDx™ Announces New Contract with MediNcrease Health Plans for its Novel DCIS Test, DCISionRT®

LAGUNA HILLS, Calif., Feb. 28, 2023 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it has ...
pix11

PreludeDx™ Enters into Agreement with Medical Cost Containment Professionals, LLC to Process Out-of-Network Claims for its Novel DCIS Test, DCISionRT®

LAGUNA HILLS, Calif., Jan. 24, 2023 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it has ...
La Grande Observer

Hannah Storm, Award-Winning Broadcaster and DCIS Patient Advocate, Partners with PreludeDx to Share How the DCISionRT Test Gave Her Confidence in Her Treatment Decision

LAGUNA HILLS, Calif., Feb. 12, 2025 /PRNewswire/ — Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, today announced a partnership with Hannah Storm, ...